Thrombocytopoietin, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation
Conditions
Brief summary
The purpose of this study is to determine whether recombinant human thrombopoietin are effective in peripheral blood progenitor cells mobilization for autologous transplantation.
Interventions
Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
Sponsors
Hongnan Mo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* a histologically confirmed diagnosis of Hodgkin's disease, non-Hodgkin's lymphoma, or selected high-risk solid tumors that are planned to receive autologous peripheral blood progenitor cell transplantation * Eastern Cooperative Oncology Group performance status of 0 - 2.
Exclusion criteria
* abnormal liver function (aminotransferase or bilirubin levels 2 times upper limit of normal), leukopenia (white blood cell count 3000/L), or a history of platelet or other disorders associated with a bleeding diathesis * a history of thromboembolic disease, coronary heart disease,stroke, arrhythmias, central nervous system metastases,or other organ system diseases or abnormalities that might predispose individuals to treatment-related complications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the average number of cluster of differentiation 34 positive cells/kg | up to 24 months | To evaluate the effect of combining various treatment schedules of recombinant human thrombopoietin with granulocyte colony stimulating factor on the mobilization of peripheral blood progenitor cells. |
Countries
China
Contacts
Primary ContactHongnan Mo, MD
Outcome results
None listed